RESOURCES
FEATURED PROJECTS
-
-
-
March 25, 2026Share
Overcoming ADC Resistance: Construction and Preclinical Applications of Enhertu-Resistant Models
Antibody-drug conjugates (ADCs), particularly the HER2-targeting Enhertu (DS-8201), have revolutionized targeted cancer therapy. Despite their clinical success, drug resistance remains a major hurdle limiting long-term therapeutic benefits. To address this challenge, GemPharmatech has developed multiple ADC resistance models, including a HER2-positive JIMT-1 breast cancer xenograft (CDX) model with acquired resistance to Enhertu, and a primary Enhertu-resistant HER2-positive lung cancer model from our patient-derived xenograft (PDX) library. Join us to explore how these Enhertu-resistant models serve as translational tools to elucidate resistance mechanisms and evaluate novel therapeutic strategies.
-
-
-
-
July 10, 2025
Knockout All Project (KOAP): Genetically Modified Mouse Models and their Applications
Join us for an exclusive webinar exploring GemPharmatech’s ambitious Knockout All Project (KOAP), a large-scale initiative to systematically generate knockout (KO) and conditional knockout (cKO) mouse strains for all ~23,000 protein coding genes in the mouse genome.
-
-
-
-
June 04, 2025
Murine Models for Heart Failure Research
Heart failure (HF), a leading global cause of mortality, affects over 64 million people worldwide, with rising prevalence driven by aging populations and increasing comorbidities. Based on left ventricular ejection fraction (LVEF), HF is classified into two primary subtypes: HF with reduced ejection fraction (HFrEF; LVEF <40%), which is characterized by impaired systolic contraction, frequently secondary to ischemic injury; and HF with preserved ejection fraction (HFpEF; LVEF ≥50%), which is defined by diastolic dysfunction with ventricular stiffness, predominantly linked to hypertension, metabolic disorders, and aging.
Hypertrophic cardiomyopathy (HCM), a genetic disorder causing pathological left ventricular hypertrophy and diastolic impairment, represents a significant etiological contributor to both HF subtypes, particularly HFpEF.
In this webinar, GemPharmatech’s Dr. Qi Xiao will introduce diverse preclinical models developed for different applications in acceleration of therapeutic discovery.
-
-
-
-
June 01, 2025
Preclinical Strategies to Evaluate T-Cell Engagers
-
-
-
-
May 06, 2025
Targeted B-Cell Therapies: Challenges and Preclinical Evaluation Considerations for Repurposing from Oncology to Autoimmunity
While targeted therapies such as B-cell depletion and immune modulation have revolutionized treatment for B-cell malignancies, recent efforts to repurpose these therapies for autoimmune diseases, for example systemic lupus erythematosus (SLE), have gained traction. However, translating oncology-focused B-cell therapies to autoimmune diseases requires addressing fundamental differences in disease pathophysiology, therapeutic goals, and safety profiles. In this webinar, we will outline key challenges and preclinical evaluation considerations to help you navigate this cross-disciplinary transition.
-
-
-
-
April 03, 2025
Drug Resistance Models in Mice: Mechanisms, Establishment and Applications
Drug resistance remains a major obstacle to effective cancer treatments. In this webinar, we will explore how advanced preclinical models including drug resistant tumor lines and novel animal models are being leveraged to unravel resistance mechanisms. Attendees will gain insight into how these models are established, validated and applied to dissecting the molecular pathways driving resistance.
-
-
-
-
November 10, 2024
Latest Technology Advances in Antibody Drug Discovery
-
